1. Home
  2. CCJ vs ALNY Comparison

CCJ vs ALNY Comparison

Compare CCJ & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cameco Corporation

CCJ

Cameco Corporation

HOLD

Current Price

$119.39

Market Cap

58.4B

ML Signal

HOLD

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

HOLD

Current Price

$323.34

Market Cap

52.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCJ
ALNY
Founded
1987
2002
Country
Canada
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.4B
52.9B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
CCJ
ALNY
Price
$119.39
$323.34
Analyst Decision
Buy
Strong Buy
Analyst Count
6
27
Target Price
$114.38
$474.42
AVG Volume (30 Days)
5.1M
1.7M
Earning Date
02-13-2026
02-12-2026
Dividend Yield
0.15%
N/A
EPS Growth
364.36
N/A
EPS
0.87
0.33
Revenue
$2,487,042,049.00
$3,210,070,000.00
Revenue This Year
$10.50
$70.40
Revenue Next Year
$8.14
$44.32
P/E Ratio
$130.99
$994.86
Revenue Growth
23.88
53.24
52 Week Low
$35.00
$205.87
52 Week High
$135.24
$495.55

Technical Indicators

Market Signals
Indicator
CCJ
ALNY
Relative Strength Index (RSI) 54.51 27.93
Support Level $109.00 $333.00
Resistance Level $128.15 $355.49
Average True Range (ATR) 6.88 11.90
MACD -2.00 -1.11
Stochastic Oscillator 37.93 2.46

Price Performance

Historical Comparison
CCJ
ALNY

About CCJ Cameco Corporation

Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. It has three reportable segments, Uranium, Fuel Services, and Westinghouse. It derives maximum revenue from the Westinghouse Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre, and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia, and the United States.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: